Abstract:

In 2020, the World Health Organization (WHO) proposed the all-oral treatment for drug-resistant pulmonary tuberculosis. Analysis showed that the success rate of all-oral treatment is higher than that of the treatment regimen containing injection. Although WHO guidelines recommend all-oral treatment regimen for different drug-resistant pulmonary tuberculosis patients, some drugs or dosages are not suitable for Chinese patients. There is no consensus on all-oral treatment for drug-resistant pulmonary tuberculosis patients in China. In order to formulate all-oral treatment for drug-resistant pulmonary tuberculosis in China, the Chinese Antituberculosis Association, Beijing Chest Hospital Affiliated to Capital Medical University and the Editorial Board of Chinese Journal of Antituberculosis jointly organized experts to write the “Chinese expert consensus on the all-oral treatment of drug-resistant pulmonary tuberculosis (2021 Edition)” (referred to as “Consensus”). Based on the research progress of all-oral treatment for drug-resistant pulmonary tuberculosis at home and abroad in recent years, this consensus recommends suitable all-oral treatment for patients with drug-resistant pulmonary tuberculosis in China, including the types and dosages of drugs used, and the types of patients and their applications and exclusion criteria. In addition, the relevant questions that may be encountered in the treatment are answered, and the precautions for the use of the plan are also emphasized, in order to improve the diagnosis and treatment of drug-resistant pulmonary tuberculosis in China.

Key words: Tuberculosis,pulmonary, Drug resistance, Clinical protocols, Administration,oral, Consensus development conferences as topic